Targeting α7 neuronal acetylcholine receptors (nAChRs) with selective agonists and positive allosteric modulators (PAMs) is considered a therapeutic approach for managing cognitive deficits in schizophrenia and Alzheimer's disease. A-867744 is a novel type II PAM with good potency and selectivity.
In vitro: In oocytes expressing α7 nAChRs, A-867744 potentiated acetylcholine (ACh)-evoked currents, with an EC50 value of about 1 μM. At highest concentrations of A-867744 tested, ACh-evoked currents were essentially nondecaying. At lower concentrations, no evidence of a distinct secondary component was evident in contrast to 4-naphthalen-1-yl-3a,4,5,9b-tetrahydro -3H-cyclopent-a[c]quinoline-8-sulfonic acid amide (TQS), another type II α7 PAM [1].
In vivo: A-867744 was assessed for its PK properties in rat, dog, and monkey. The animal pharmacokinetic profile of A-867744 was characterized by relatively low plasma clearance values (1.1-2.5 L/h/kg) and volumes of distribution (1.7-4.6 L/kg) across species, with terminal elimination halflives in the 1.0-1.7 h. The bioavailability is 83% in rat and somewhat lower in dog (55%) and monkey (68%). These findings indicated that A-867744 showed acceptable pharmacokinetic profile across species and brain levels sufficient to modulate α7 nAChRs [2].
Clinical trial: A-867744 is currently in the preclinical developlent stage and no clinical data are available.
Reference:
[1] Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, Wetterstrand C, Briggs CA, Faghih R, Bunnelle WH, Gopalakrishnan M.
In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl) (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther. 2009;330(1):257-67.
[2] Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, Ween H, Curtis MP, Sarris KA, Gfesser GA, El-Kouhen R, Robb HM, Radek RJ, Marsh KC, Bunnelle WH, Gopalakrishnan M. Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl) benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. J Med Chem. 2009;52(10):3377-84.
A-867744
目录号: GC15014纯度: >99.50%同义词: 4-[5-(4-氯苯基)-2-甲基-3-丙酰基吡咯-1-基]苯磺酰胺,A 867744;A867744
A positive allosteric modulator of α7 nAChRs
Cas No.: 1000279-69-5
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 10mg | ¥834.00 | 现货 | 1 | |
| 50mg | ¥3,780.00 | 现货 | 1 | |
| 100mg | ¥6,430.00 | 现货 | 1 |
电话: 400-920-5774Email: sales@glpbio.cn
文献被引
本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
Nature641, 529–536 (2025)
Nature628, 630–638 (2024)
Nature632, 686–694 (2024)
Nature618, 1017–1023 (2023)
Nature610, 366–372 (2022)
Cell187(9):2288-2304 (2024)
Cell183(7):1867-1883 (2020)
Science388(6745) (2025)
Science387(6739) (2025)
Science387(6734) (2025)
Cell Research35, 97–116 (2025)
Cell Research34, 683–706 (2024)
Cell Research33, 273–287 (2023)
Cell Research33, 546–561 (2023)
Cell Research33, 904–922 (2023)
Cell Research31, 1291–1307 (2021)
产品描述 Description
产品文档 Product Documents
Purity:>99.50%
化学性质Chemical Properties
CAS 号
1000279-69-5
同义词
4-[5-(4-氯苯基)-2-甲基-3-丙酰基吡咯-1-基]苯磺酰胺,A 867744;A867744
化学名
4-[5-(4-chlorophenyl)-2-methyl-3-propanoylpyrrol-1-yl]benzenesulfonamide
SMILES
CCC(=O)C1=C(N(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)S(=O)(=O)N)C
分子式
C20H19ClN2O3S
分子量
402.89 g/mol
溶解性
DMF: 30 mg/ml,DMF:PBS (pH 7.2) (1:4): 0.20 mg/ml,DMSO: 10 mg/ml
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。
计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度
g/mol
